Helpline
+91 8892 555 000
Email : contactus@ordindia.in

Alexion completes purchase and licence agreement for early-stage rare disease gene therapy portfolio from Pfizer

Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and license agreement for a portfolio of preclinical rare disease gene therapy programes and enabling technologies from Pfizer Inc. (Pfizer). These...

Read More

ORDI News Letter August 2023

...

Read More

New GAA mutations linked to infantile-onset disease

Three new mutations in the GAA gene were linked with heart disease and severe breathing problems in infants with infantile-onset Pompe disease (IOPD) in Malaysia, a study reports. “The novel mutations identified in this...

Read More

Gene therapy: Human trials to begin in Karnataka for treatment of genetic disorders

Gene therapy work was started 10 years ago under the guidance of founder and former chairman Dr K Bhujang Shetty. BENGALURU: Gene therapy human trials will be initiated in India for...

Read More

PANEL DISCUSSION

...

Read More

Patient Summit Together for Better Health

Boehringer Ingelheim   Our team from the India, Middle East, Turkey, and Africa region recently organized a rare disease summit, bringing together healthcare professionals, patient organization representatives, and policy makers....

Read More

Recommendations of 50th meeting of GST Council

Link for original article...

Read More

ORDI Newsletter June 2023

...

Read More

The gift of early detection: All you need to know about newborn screening

June 28 is International Newborn Screening Day. The purpose of newborn screening is to identify conditions which can be treated, especially if caught early, so that affected children can live...

Read More

KEM Hospital’s Rare Diseases Centre crippled by lack of infrastructure

KEM Hospital, one of the 11 Centres of Excellence (CoE) for Rare Diseases in India, is facing challenges in fulfilling its mandate due to a lack of designated space and...

Read More

Highslide for Wordpress Plugin